Skip to main content
GutCited

Saccharomyces boulardii के लिए Clostridioides difficile Infection (CDI)

B

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'gutcited.com'; const params = 'ingredient\u003Dsaccharomyces\u002Dboulardii\u0026condition\u003Dclostridioides\u002Ddifficile'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

B

निष्कर्ष

Meta-analyses show S. boulardii reduces CDI recurrence by 50-60% when given as adjunct to standard antibiotic treatment. Strongest evidence for preventing recurrent CDI.

Key Study Findings

Review
The evidence for probiotics in the treatment of digestive disorders in the pediatric population.
Dose: None बनाम: None Outcome: None प्रभाव: None None

जनसंख्या: Pediatric population

Review
Clostridioides difficile Infections: Prevention and Treatment Strategies.
Dose: None बनाम: None Outcome: C. difficile infection treatment outcomes प्रभाव: None None

जनसंख्या: Patients with C. difficile infection

Review 520 weeks
Qualitative Analysis of the Efficacy of Probiotic Strains in the Prevention of Antibiotic-Associated Diarrhea.
Dose: None बनाम: None Outcome: None प्रभाव: None None

जनसंख्या: None

Review
Clostridium difficile Colitis Prevention and Treatment.
Dose: None बनाम: None Outcome: Diarrhea outcomes प्रभाव: None None

जनसंख्या: None

Systematic Review n=228
Strain-Specificity and Disease-Specificity of Probiotic Efficacy: A Systematic Review and Meta-Analysis.
Dose: None बनाम: None Outcome: Diarrhea outcomes प्रभाव: None None

जनसंख्या: None

Review
Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?
Dose: None बनाम: None Outcome: GI condition outcomes (C. diff, AAD, H. pylori) प्रभाव: None None

जनसंख्या: Adults with GI conditions

Key Statistics

6

अध्ययन

3000

प्रतिभागी

Positive

B

ग्रेड

Referenced Papers

Journal of gastroenterology … 2025 10 उद्धरण
Advances in experimental … 2024 2 उद्धरण
Advances in experimental … 2019 17 उद्धरण
The American journal … 2018 46 उद्धरण
Journal of pediatric … 2016 233 उद्धरण
Clinical and experimental … 2016 82 उद्धरण
Journal of clinical … 2011 432 उद्धरण
American journal of … 2010
Current opinion in … 2009 82 उद्धरण
The American journal … 2001 648 उद्धरण
International journal of … 2000 181 उद्धरण
Clinical infectious diseases … 1998 346 उद्धरण

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

सामान्य रूप से उपयोग की जाने वाली खुराकें

general:
250-500 mg/day (equivalent to 5-10 billion CFU)
aadprevention:
500 mg/day (start with antibiotic, continue 7 days after)
cdiffprevention:
500 mg twice daily as adjunct to standard therapy
travelersdiarrhea:
250-500 mg/day starting 5 days before travel

अधिकतम सीमा: Well-tolerated up to 1,000 mg/day in clinical trials

अनुसंधान में अध्ययन की गई खुराकें

खुराक अवधि प्रभाव N
None -- Mixed --
None -- Positive --
None 520 weeks Positive --
None -- Mixed --
None -- Mixed 228
None -- Mixed --
None -- Mixed --
None -- Mixed --

सेवन का सर्वोत्तम समय: Can be taken with or without food; space 2 hours from antifungals

Safety & Side Effects

रिपोर्ट किए गए दुष्प्रभाव

  • Mild gas and bloating
  • Rare: fungemia in critically ill patients with central venous catheters
  • Thirst (yeast may increase water requirements)
  • Very rare: potential environmental contamination risk in ICU settings

ज्ञात अंतःक्रियाएँ

  • Antifungal medications (may kill S. boulardii, reducing effectiveness)
  • Monoamine oxidase inhibitors (S. boulardii contains tyramine)
  • Immunosuppressants (theoretical risk of fungemia in immunocompromised patients)

सहनीय अधिकतम सेवन: Well-tolerated up to 1,000 mg/day in clinical trials

कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।

Frequently Asked Questions

Does Saccharomyces boulardii help with Clostridioides difficile Infection (CDI)?
Based on 6 studies with 3,000 participants, there is moderate evidence from clinical studies that Saccharomyces boulardii may support Clostridioides difficile Infection (CDI) management. Our evidence grade is B (Good Evidence).
How much Saccharomyces boulardii should I take for Clostridioides difficile Infection (CDI)?
Studies have used various dosages. A commonly studied range is 250-500 mg/day (equivalent to 5-10 billion CFU). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Saccharomyces boulardii?
Reported side effects may include Mild gas and bloating, Rare: fungemia in critically ill patients with central venous catheters, Thirst (yeast may increase water requirements), Very rare: potential environmental contamination risk in ICU settings. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Saccharomyces boulardii and Clostridioides difficile Infection (CDI)?
We rate the evidence as Grade B (Good Evidence). This rating is based on 6 peer-reviewed studies with 3,000 total participants. The overall direction of effect is positive.

Related Evidence

Saccharomyces boulardii अन्य स्वास्थ्य स्थितियों के लिए

FDA अस्वीकरण: इन कथनों का Food and Drug Administration द्वारा मूल्यांकन नहीं किया गया है। इस वेबसाइट पर उत्पादों और जानकारी का उद्देश्य किसी बीमारी का निदान, उपचार, इलाज या रोकथाम नहीं है। प्रस्तुत साक्ष्य ग्रेड प्रकाशित पीयर-रिव्यूड अनुसंधान के हमारे विश्लेषण पर आधारित हैं और चिकित्सा सलाह नहीं हैं। कोई भी सप्लीमेंट शुरू करने से पहले हमेशा अपने स्वास्थ्य सेवा प्रदाता से परामर्श करें।